The present invention is directed to methods of treating AERD (aspirin exacerbated respiratory disease) and/or asthma via the administration of a thromboxane receptor antagonist to a patient in need thereof.

The present invention is directed to methods of treating AERD (aspirin exacerbated respiratory disease) and/or asthma via the administration of a thromboxane receptor antagonist to a patient in need thereof.

One aspect of the invention provides a method for treatment of a lysosomal storage disorder. The method may include administering to a subject in need of such treatment a composition including a therapeutically effective amount of an agent that mediates upregulation of Transcription Factor EB. In one embodiment, the composition includes a fibrate, such as gemfibrozil or fenofibrate. In another embodiment, the composition also includes all-trans retinoic acid or vitamin A.

One aspect of the invention provides a method for treatment of a lysosomal storage disorder. The method may include administering to a subject in need of such treatment a composition including a therapeutically effective amount of an agent that mediates upregulation of Transcription Factor EB. In one embodiment, the composition includes a fibrate, such as gemfibrozil or fenofibrate. In another embodiment, the composition also includes all-trans retinoic acid or vitamin A.

One aspect of the invention provides a method for treatment of a lysosomal storage disorder. The method may include administering to a subject in need of such treatment a composition including a therapeutically effective amount of an agent that mediates upregulation of Transcription Factor EB. In one embodiment, the composition includes a fibrate, such as gemfibrozil or fenofibrate. In another embodiment, the composition also includes all-trans retinoic acid or vitamin A.

The present invention relates to a device for delivering acetylsalicylic acid or a salt thereof for the administration thereof through oral inhalation route for the preventive or curative treatment of thrombohemolytic events, in particular for myocardial infarction.

The present invention relates to a device for delivering acetylsalicylic acid or a salt thereof for the administration thereof through oral inhalation route for the preventive or curative treatment of thrombohemolytic events, in particular for myocardial infarction.

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to a therapeutic treatment or prevention of viral infections such as, for example, COVID-19. In one aspect, the therapeutic treatment combines the administration of doxycycline and/or chemically-modified tetracyclines with resveratrol and ivermectin. In another aspect, the disclosed treatment offers anti-inflammatory effects, can combat the effects of reactive oxygen species, and can inhibit the activity of matrix metalloproteinase enzymes; these combined effects may, in some aspects, be useful in preventing or mediating the effects of the cytokine storm that is associated with poor COVID-19 outcomes including death. In some aspects, dosages of the treatment can be modified to account for COVID-19 comorbidities including, but not limited to, such conditions as diabetes or hypertension.

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to a therapeutic treatment or prevention of viral infections such as, for example, COVID-19. In one aspect, the therapeutic treatment combines the administration of doxycycline and/or chemically-modified tetracyclines with resveratrol and ivermectin. In another aspect, the disclosed treatment offers anti-inflammatory effects, can combat the effects of reactive oxygen species, and can inhibit the activity of matrix metalloproteinase enzymes; these combined effects may, in some aspects, be useful in preventing or mediating the effects of the cytokine storm that is associated with poor COVID-19 outcomes including death. In some aspects, dosages of the treatment can be modified to account for COVID-19 comorbidities including, but not limited to, such conditions as diabetes or hypertension.

The instant invention provides a process for reducing the drying time of softgel capsules by incorporating drying accelerators based on organic sulfonic acids and salts thereof into the formulations used to make the capsules.